The Multiple Myeloma market report provides current treatment practices, emerging drugs, MM market share of the individual therapies, current and forecasted MM market size from 2017 to 2030 segmented by eight major markets. The Report also covers current MM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Multiple Myeloma Overview
Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females.
Download free sample copy- https://www.delveinsight.com/sample-request/multiple-myeloma-market
List of regions covered in the report
List of Multiple Myeloma companies involved in the report
Multiple Myeloma Diagnosis
Multiple myeloma is often diagnosed based on tests, the patient’s symptoms and the doctor’s physical exam of the patient. A diagnosis of multiple myeloma requires either:
1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow
2. At least one of the following:
Multiple Myeloma Treatment
The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.
Multiple Myeloma Market Drugs
The drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Multiple Myeloma Marketed Drugs
Multiple Myeloma Emerging Drugs
Multiple Myeloma Market Report Scope
Table of Content
1. Key Insights
2. Report Introduction
3. Multiple Myeloma Market Overview at a Glance
4. Executive Summary of Multiple Myeloma
5. Epidemiology and Market Forecast Flow
6. Disease Background and Overview
7. Diagnosis of Multiple Myeloma
8. Treatment
9. Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints in Multiple Myeloma
12. Marketed Therapies
13. Emerging Therapies
14. Multiple Myeloma: Eight Major Market Analysis
15. Market Access and Reimbursement of Multiple Myeloma Therapies
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Multiple Myeloma Market Report Highlights
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/